e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Respiratory epidemiology: quality of life, therapy and socioeconomics
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic population model for COPD
M. Hoogendoorn, M. Rutten-van Mölken, R. Hoogenveen, M. Al, T. Feenstra (Rotterdam, Bilthoven, Groningen, Netherlands)
Source:
Annual Congress 2011 - Respiratory epidemiology: quality of life, therapy and socioeconomics
Session:
Respiratory epidemiology: quality of life, therapy and socioeconomics
Session type:
Thematic Poster Session
Number:
4126
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Hoogendoorn, M. Rutten-van Mölken, R. Hoogenveen, M. Al, T. Feenstra (Rotterdam, Bilthoven, Groningen, Netherlands). Comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic population model for COPD. Eur Respir J 2011; 38: Suppl. 55, 4126
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Prediction models for exacerbations in different COPD patient populations: Results of five large databases
Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD
Year: 2016
Evaluating COPD disease management: application of a theoretical model
Source: Annual Congress 2008 - Issues in the management of COPD in the community
Year: 2008
Real-life COPD patients compared to large trial populations: An UNLOCK external validity study
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013
Comparison of multidimensional assessment systems with regard to risk prediction for exacerbations of COPD
Source: Annual Congress 2011 - COPD exacerbation
Year: 2011
Modeling the cost-effectiveness of stratified medicine in COPD
Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care
Year: 2017
A Markov model based on COPD disease severity to analyse the results from tiotropium trials
Source: Eur Respir J 2002; 20: Suppl. 38, 125s
Year: 2002
A general framework to implement predictive models for hospitalizations: Application to COPD
Source: International Congress 2017 – Best abstracts in the management of chronic respiratory diseases
Year: 2017
External validation of exacerbation and mortality outcomes of health economic decision models for COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016
Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Comparison of five major airflow limitation criteria to identify high-risk individuals with COPD in the general population
Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases
Year: 2020
Efficiency of different approaches for the assessment of the risk of exacerbations in patients with COPD
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019
Forecasting model for illness behavior types in COPD patients
Source: International Congress 2019 – Innovations in care for chronic respiratory conditions
Year: 2019
A global survey conducted to determine frequency of exacerbations in COPD patients
Source: Annual Congress 2013 –COPD treatment
Year: 2013
The effect of different tools in assessing the prevalence of depression in COPD patients
Source: Annual Congress 2008 - Quality of life and mood disturbances in rehabilitation
Year: 2008
Characteristics of effective self-management interventions in patients with COPD: individual patient data meta-analysis
Source: Eur Respir J 2016; 48: 55-68
Year: 2016
Quantifying comorbidity in individuals with COPD: a population study
Source: Eur Respir J 2015; 45: 51-59
Year: 2015
Cost and effectiveness of 2 years integrated care intervention in COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Costs of COPD exacerbations in a general population.
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Comparison of COPD patients with high and low symptoms from a real-world US survey
Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases
Year: 2015
COPD severity and health impact across the current CanCOLD population
Source: Annual Congress 2012 - COPD: epidemiology and varia
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept